Loading...
•
Mar 31, 2022
AcelRx Q1 2022 Earnings Report
AcelRx reported first quarter 2022 financial results, highlighting DSUVIA sales growth and a strategic shift towards development.
Key Takeaways
AcelRx Pharmaceuticals reported $0.4 million in net revenues for Q1 2022. The company is realigning its cost structure to focus on development, expecting $9 million in annual savings. DSUVIA sales continued to grow, with a 64% increase in commercial sales compared to the previous quarter.
Realigned cost structure to prioritize development, projecting $9 million in annual savings.
Completed the acquisition of Lowell Therapeutics, including the Niyad franchise.
DSUVIA sales momentum continued with fourth consecutive quarter of sales volume growth.
Cash and short-term investments totaled $39.3 million as of March 31, 2022.
AcelRx
AcelRx
Forward Guidance
AcelRx anticipates near-term value creation through its development pipeline, including NDA submissions for pre-filled syringes in 2022 and potential emergency use authorization for Niyad in 2023. The company also intends to reduce operating costs and explore partnerships for DSUVIA.
Positive Outlook
- Planned NDA submissions for pre-filled syringes in 2022.
- Potential emergency use authorization for Niyad in 2023.
- Focus on procedural suite sales.
- Pursuing partnerships for DSUVIA.
- Expected cost savings from corporate restructuring.
Challenges Ahead
- Risk that restructuring could adversely affect the ability to successfully market DSUVIA.
- Risks relating to obtaining regulatory approvals for product candidates.
- Risks related to product development activities diverting management's attention.
- Risks related to the ability to implement development plans and forecasts.
- Risks related to unexpected variations in market growth and demand.